LYDIA71
2021-09-27
Like pls
Exscientia Sets IPO at 13.1 Million ADSs; Sees Pricing at $20-$22 Each
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":866828435,"tweetId":"866828435","gmtCreate":1632754720127,"gmtModify":1632798060378,"author":{"id":3568626920493898,"idStr":"3568626920493898","authorId":3568626920493898,"authorIdStr":"3568626920493898","name":"LYDIA71","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/866828435","repostId":1104751854,"repostType":4,"repost":{"id":"1104751854","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1632753249,"share":"https://www.laohu8.com/m/news/1104751854?lang=&edition=full","pubTime":"2021-09-27 22:34","market":"us","language":"en","title":"Exscientia Sets IPO at 13.1 Million ADSs; Sees Pricing at $20-$22 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1104751854","media":"Dow Jones","summary":"Exscientia PLC on Monday said it plans to sell nearly 13.1 million American depositary shares at bet","content":"<p>Exscientia PLC on Monday said it plans to sell nearly 13.1 million American depositary shares at between $20 and $22 apiece in its initial public offering.</p>\n<p>At the $21 midpoint of that range, the Oxford, U.K., clinical-stage pharmatech company said it expects net proceeds of about $249.2 million, or roughly $287.6 million if the underwriters exercise an option to buy an additional 1.96 million ADSs.</p>\n<p>Exscientia said it also expects to net about $151.3 million from concurrent private placements of $125 million with an affiliate of SoftBank Group Corp. and $35 million with the Bill & Melinda Gates Foundation.</p>\n<p>Exscientia, which is using artificial intelligence to design patient-based drugs, said it believes the proceeds from the IPO and private placements, coupled with its existing resources, will be sufficient to fund its operations and capital-spending needs for at least a year.</p>\n<p>Each Exscientia represents one ordinary share. In a filing with the U.S. Securities and Exchange Commission, Exscientia said it would have about 119.9 million shares outstanding after the IPO and private placements, assuming exercise of the overallotment option, for a market capitalization topping $2.5 billion at the $21-a-share pricing midpoint.</p>\n<p>Exscientia said it has applied to list its ADSs on the Nasdaq Global Select Market under the symbol EXAI.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exscientia Sets IPO at 13.1 Million ADSs; Sees Pricing at $20-$22 Each </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExscientia Sets IPO at 13.1 Million ADSs; Sees Pricing at $20-$22 Each \n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-27 22:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exscientia PLC on Monday said it plans to sell nearly 13.1 million American depositary shares at between $20 and $22 apiece in its initial public offering.</p>\n<p>At the $21 midpoint of that range, the Oxford, U.K., clinical-stage pharmatech company said it expects net proceeds of about $249.2 million, or roughly $287.6 million if the underwriters exercise an option to buy an additional 1.96 million ADSs.</p>\n<p>Exscientia said it also expects to net about $151.3 million from concurrent private placements of $125 million with an affiliate of SoftBank Group Corp. and $35 million with the Bill & Melinda Gates Foundation.</p>\n<p>Exscientia, which is using artificial intelligence to design patient-based drugs, said it believes the proceeds from the IPO and private placements, coupled with its existing resources, will be sufficient to fund its operations and capital-spending needs for at least a year.</p>\n<p>Each Exscientia represents one ordinary share. In a filing with the U.S. Securities and Exchange Commission, Exscientia said it would have about 119.9 million shares outstanding after the IPO and private placements, assuming exercise of the overallotment option, for a market capitalization topping $2.5 billion at the $21-a-share pricing midpoint.</p>\n<p>Exscientia said it has applied to list its ADSs on the Nasdaq Global Select Market under the symbol EXAI.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXAI":"Exscientia plc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104751854","content_text":"Exscientia PLC on Monday said it plans to sell nearly 13.1 million American depositary shares at between $20 and $22 apiece in its initial public offering.\nAt the $21 midpoint of that range, the Oxford, U.K., clinical-stage pharmatech company said it expects net proceeds of about $249.2 million, or roughly $287.6 million if the underwriters exercise an option to buy an additional 1.96 million ADSs.\nExscientia said it also expects to net about $151.3 million from concurrent private placements of $125 million with an affiliate of SoftBank Group Corp. and $35 million with the Bill & Melinda Gates Foundation.\nExscientia, which is using artificial intelligence to design patient-based drugs, said it believes the proceeds from the IPO and private placements, coupled with its existing resources, will be sufficient to fund its operations and capital-spending needs for at least a year.\nEach Exscientia represents one ordinary share. In a filing with the U.S. Securities and Exchange Commission, Exscientia said it would have about 119.9 million shares outstanding after the IPO and private placements, assuming exercise of the overallotment option, for a market capitalization topping $2.5 billion at the $21-a-share pricing midpoint.\nExscientia said it has applied to list its ADSs on the Nasdaq Global Select Market under the symbol EXAI.","news_type":1},"isVote":1,"tweetType":1,"viewCount":456,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/866828435"}
精彩评论